Cell头条：向大脑中注射基因改造的寨卡病毒，治疗致命脑肿瘤

Core Viewpoint - The research published in Cell Reports Medicine explores the safety and potential of a genetically modified Zika virus (Δ10 3′-UTR ZIKV) for treating glioblastoma, a highly aggressive brain tumor, showing promising results in primates [3][6][10]. Group 1: Glioblastoma Overview - Glioblastoma (GBM) has a median survival of less than 21 months, with standard treatments showing limited efficacy [6]. - The tumor's high heterogeneity and immunosuppressive microenvironment contribute to treatment resistance and recurrence within six months post-treatment [6]. Group 2: Oncolytic Virus Therapy - Oncolytic viruses, including various types, are being researched for their ability to selectively target and destroy tumor cells, offering a potential new treatment strategy for GBM [7]. - Zika virus (ZIKV) has shown unique properties in specifically targeting glioblastoma stem cells (GSCs), reducing tumor volume and extending survival in mouse models [7][9]. Group 3: Research Findings - The modified Zika virus (Δ10 3′-UTR ZIKV) was shown to be safe in non-tumor rhesus monkeys, with no clinical signs of disease and only mild localized inflammation observed [9][10]. - The virus did not revert to its wild type, and infectious strains were not isolated post-injection, indicating a favorable safety profile for potential clinical applications [10]. - ZIKV RNA was cleared from the blood of monkeys within one week post-injection, further supporting its safety for brain applications [10].